Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA6 | P23280 | 3/20 | 0.38 |
| ▸ | CA7 | P43166 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.38 |
| ▸ | CASP2 | P42575 | 2/20 | 0.38 |
| ▸ | F13A1 | P00488 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 2/20 | 0.38 |
| ▸ | CA5A | P35218 | 2/20 | 0.38 |
| ▸ | THPO | P40225 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9543583 | 0.93 | CA12 (0.40) | CA12CA6CA7CA9CA14 | |
| SCHEMBL28697622 | 0.91 | PAOX (0.39) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3345454 | 0.84 | — | — | |
| SCHEMBL1742138 | 0.75 | ACHE (0.31) | — | |
| SCHEMBL3346318 | 0.73 | — | — | |
| SCHEMBL9215586 | 0.70 | — | — | |
| SCHEMBL4413907 | 0.70 | — | — | |
| SCHEMBL6228460 | 0.70 | — | — | |
| SCHEMBL25450601 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL9217063 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1890703-B1 | PYRIMIDINE COMPOUNDS AS CHEMOKINE RECEPTORS INHIBITORS | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2016-05-11 | — | — | EP | disclosed |
| US-8193206-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2012-06-05 | — | — | US | disclosed |
| US-7589197-B2 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2009-09-15 | — | — | US | disclosed |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-06-04 | — | — | US | disclosed |
| EP-1890703-A2 | PYRIMIDINE COMPOUNDS | Taigen Biotechnology (TW) | 2008-02-27 | — | — | EP | disclosed |
| US-20060293324-A1 | Pyrimidine compounds | GPCR THERAPEUTICS, INC (KR) | 2006-12-28 | — | — | US | disclosed |
| WO-2006138304-A2 | PYRIMIDINE COMPOUNDS | TAIGEN BIOTECHNOLOGY (TW) | 2006-12-28 | — | — | WO | disclosed |
| US-20060281712-A1 | Pyrimidine compounds | TAIGEN BIOTECHNOLOGY (TW) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281712-A1 | Pyrimidine compounds | TYMS, TYMP, HPRT1 | CA12 4771/4885CA6 3766/4885CA7 4758/4885 |
| US-20090143302-A1 | PYRIMIDINE COMPOUNDS | TYMS, TYMP, HPRT1 | CA12 4771/4885CA6 3766/4885CA7 4758/4885 |
| US-20060293324-A1 | Pyrimidine compounds | TYMS, TYMP, HPRT1 | CA12 4771/4885CA6 3766/4885CA7 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.